Format

Send to

Choose Destination
Expert Rev Cardiovasc Ther. 2007 Nov;5(6):1037-46.

Insight into ACE inhibition in the prevention of cardiac events in stable coronary artery disease: the EUROPA trial.

Author information

1
Chair of Cardiology, University of Ferrara, Arcispedale S. Anna, Corso Giovecca 203, 44100, Ferrara, Italy. fri@unife.it

Abstract

The European Trial on Reduction of Cardiac Events with Perindopril in Stable Coronary Artery Disease (EUROPA) investigated the effect of angiotensin-converting enzyme inhibition on the prevention of cardiac events in patients with stable coronary artery disease (CAD) without apparent heart failure. Perindopril 8 mg/day significantly reduced a composite outcome of cardiovascular death, nonfatal myocardial infarction or resuscitated cardiac arrest by 20% compared with placebo, in addition to standard preventive therapies. This review describes the substudies and subpopulation analyses carried out within the EUROPA population, concluding that the benefits of perindopril extend to all stable CAD patients, even revascularized patients or those with preserved left ventricular function. Data on the pathophysiological mechanisms underlying CAD indicate direct vascular protection with perindopril. This helps explain why perindopril is beneficial in preventing cardiac events in stable CAD patients.

PMID:
18035919
DOI:
10.1586/14779072.5.6.1037
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Taylor & Francis
Loading ...
Support Center